Open Access Publisher and Free Library
CRIME+CRIMINOLOGY.jpeg

CRIME

Violent-Non-Violent-Cyber-Global-Organized-Environmental-Policing-Crime Prevention-Victimization

Posts tagged drug supply
Illicit drug markets of Eastern and Southern Africa: An overview of production, supply and use

By Jason Eligh

The countries of Eastern and Southern Africa have a long history of illicit drug cultivation, production, consumption and trade. Khat, a crop that is indigenous to the Horn and coastal East Africa, has been used as a stimulant since the 12th century. Cannabis, originally imported from Asia, has a history of several hundred years of production and use in the region.

Initially, the informal policies surrounding the control of these drugs had been driven by traditional social networks, and cultural beliefs and practices. Today, however, it is the more recent large-scale trade in and widespread use of opiates, stimulants and other synthetic substances that has become recognized as a harmful phenomenon and risk to the region. As container and intermodal shipping grew rapidly through the 1970s, along with new long-haul mass transport and passenger aircraft, the global economic landscape in general, and illicit drug marketplaces in particular, were reshaped. The development of the region’s air and seaports, and their integration into global transport and communication networks, saw the emergence of new entrepôt trade, and hubs of commerce became networked across the continent. Meanwhile, technological innovations designed to increase the volume of drug commodity movement and decrease the risk of seizure began to emerge. With these developments, many nascent networks of African drug traders began to consolidate their positions in the drug economies of Eastern and Southern Africa.

As international drug control measures began to restrict supply chains from South Asian and Latin American source points, new trafficking routes evolved in Eastern and Southern African states to circumvent these measures, thus opening new supply channels and, consequently, new markets. From the 1980s, the continental consumption, production and distribution of substances such as heroin, cocaine, cannabis and synthetic drugs grew notably, and the impact of this expanding illicit market on development was significant, and paradoxically symbiotic. The emerging illicit drug markets were both a threat to development and security in the region and at the same time a new source of economic livelihood for populations of poor and vulnerable communities.

The 1990s saw significant, rapid drug trade expansion across the continent as Afghan heroin began to emerge in volume in East Africa. Shipped by dhow to Kenyan and Tanzanian ports from Pakistan and Iranian departure points, initially to be repackaged and trans-shipped to European and US markets, local heroin use began to grow. Heroin use spread along the eastern coast and to South Africa, as well as to some island states, such as Mauritius and the Seychelles. Across the region these heroin users tended to be among the poorest and most vulnerable members of society. Injection drug use soon emerged in Zimbabwe, Zambia, Malawi, Uganda, Rwanda, Burundi, eSwatini, Namibia, Angola and the Democratic Republic of Congo (DRC). Cocaine, methamphetamine and other synthetic drugs soon followed.

Today, Eastern and Southern African countries have become significant illicit drug transit hubs and destination markets for a diversity of illicit drugs. Growing consumer demand and improved infrastructure have shaped and facilitated the availability and accessibility of illicit drugs across the region. As a consequence, domestic and regional drug trade flows and user markets have become embedded features of the region’s domestic illicit economies.

Geneva, SWIT: Global Initiative Against Transnational Organized Crime 2021. 28p.

Is fentanyl in everything? Examining the unexpected occurrence of illicit opioids in British Columbia’s drug supply

By Bruce Wallace, Irene Shkolnikov, Collin Kielty, Derek Robinson, et al.

Background Illicit opioids, including fentanyl, are linked to unprecedented levels of overdose in Canada and elsewhere. The risks associated with illicit opioids can include high potency, unpredictable concentration and the unexpected presence in other drugs. Within this context, we examine drug checking data to better understand the presence of illicit opioids such as fentanyl in other drugs and possible ways to interpret these results. Methods Three years (2021–2023) of data (18,474 samples) from Substance Drug Checking in British Columbia, Canada were examined to investigate the risks associated with the detection of opioids in other drugs such as cocaine and methamphetamine, as well as in other drug categories. Samples were tested by paper spray mass spectrometry (PS-MS), fentanyl test strips and Fourier-Transform infrared spectroscopy (FTIR). We examine the 8889 samples not expected to include fentanyl to confirm; if the expected drug was detected, if unexpected opioids were detected, and when the unexpected opioids are in trace concentration. Results Unexpected opioids were rarely detected (2%) in other drugs (189 of 8889 samples) with most (61.4%) detected at trace concentration levels. Unexpected opioids are far more likely to be found in samples that did not contain the expected drug than in samples that were confirmed to contain the expected drug. The least common scenario (below 1%) were substances that included the expected drug plus unexpected opioid above trace concentration. These findings raise questions on how to interpret and communicate the detection of fentanyl and related opioids in other drugs. We present three potential interpretations: (1) mistaken and misrepresented samples where the expected drug was never detected, (2) cross contamination when opioids were at trace concentration levels, or (3) adulteration as the least frequent scenario where opioids were detected above trace concentrations in combination with the expected drug. Conclusions In a region where fentanyl is associated with extreme rates of overdose, it remains rare to find such opioids in other drugs. However, the risk of fentanyl in other drugs remains an ongoing threat that warrants responses by individuals and public health. We provide possible interpretations to inform such responses. Our data raises questions on how to interpret and communicate the detection of fentanyl and other opioids in other drugs.

Harm Reduction Journal, (2025) 22:28, 8p.

Experiences with rising overdose incidence caused by drug supply changes during the COVID-19 pandemic in the San Diego-Tijuana border metroplex

By C.J. Valaseka , Samantha A. Streuli a, Heather A. Pines , Steffanie A. Strathdeec , Annick Borquez , Philippe Bourgois , Tara Stamos-Buesige , Carlos F. Verac , Alicia Harvey-Verac , Angela R. Bazzi

Background: People who use drugs (PWUD) in the San Diego, USA and Tijuana, Mexico metroplex face high overdose risk related to historic methamphetamine use and relatively recent fentanyl introduction into local drug supplies. The personal overdose experiences of PWUD in this region are understudied, however, and may have been influenced by the COVID pandemic. Methods: From September-November 2021, we conducted 28 qualitative interviews among PWUD ≥18 years old sampled from an ongoing cohort study in the San Diego-Tijuana metroplex. Interviews explored overdose experiences and changes in the drug supply. Thematic analysis of coded interview transcripts explored overdose experiences, perspectives on drug supply changes, interactions with harm reduction services, and naloxone access. Results: Among 28 participants, 13 had experienced an overdose. Participants discussed rising levels of fentanyl in local drug supplies and increasing overdose incidents in their social networks. Participants discussed a general shift from injecting heroin to smoking fentanyl in their networks. Participants’ most common concerns included having consistent access to a safe and potent drug supply and naloxone. Conclusion: Participants prioritized adapting to drug supply changes and preventing overdose compared to other health concerns, such as HIV and COVID-19. Efforts to address overdose in this region could benefit from drug checking services and expanded, equitable delivery of naloxone.

Volume 7, June 2023, 100154, Drug and Alcohol Dependence Reports